Immunocore (IMCR) Financials

$26.92 +0.33 (+1.24%)

As of 04/14/2025 04:00 PM Eastern

Annual Income Statements for Immunocore

This table shows Immunocore's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-91	-138	-101	-180	-53	-55	-51
Consolidated Net Income / (Loss)	-91	-138	-101	-180	-53	-55	-51
Net Income / (Loss) Continuing Operations	-91	-138	-101	-180	-53	-55	-51
Total Pre-Tax Income	-112	-167	-119	-180	-41	-61	-53
Total Operating Income	-119	-157	-119	-175	-52	-60	-70
Total Gross Profit	30	34	45	36	173	248	307
Total Revenue	30	34	50	36	174	249	310
Operating Revenue	30	34	50	36	174	249	310
Total Cost of Revenue	0.00	0.00	4.61	0.00	1.09	1.04	2.73
Operating Cost of Revenue	-	-	4.61	0.00	1.09	1.04	2.73
Total Operating Expenses	150	191	165	211	225	308	378
Selling, General & Admin Expense	44	59	62	111	123	144	156
Research & Development Expense	106	132	102	100	102	164	222
Total Other Income / (Expense), net	7.10	-10	0.00	-5.29	11	-1.24	18
Interest Expense	-5.65	12	-	5.57	5.41	5.15	19
Interest & Investment Income	1.45	2.00	-	0.07	3.76	18	26
Other Income / (Expense), net	-	-	-	0.22	12	-14	11
Income Tax Expense	-21	-29	-18	0.15	12	-5.60	-1.85
Basic Earnings per Share	($3.32)	($4.66)	($2.79)	($4.24)	($1.15)	($1.13)	($1.02)
Weighted Average Basic Shares Outstanding	-	-	31.78M	42.49M	45.71M	48.89M	49.99M
Diluted Earnings per Share	($3.32)	($4.66)	($2.79)	($4.24)	($1.15)	($1.13)	($1.02)
Weighted Average Diluted Shares Outstanding	-	-	31.78M	42.49M	45.71M	48.89M	49.99M
Weighted Average Basic & Diluted Shares Outstanding	-	-	31.78M	43.86M	48.09M	49.82M	50.07M
Cash Dividends to Common per Share	-	-	-	-	$0.00	$0.00	$0.00

This table shows Immunocore's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-19	-17	0.91	-20	-24	-12	8.74	-24
Consolidated Net Income / (Loss)	-19	-17	0.91	-20	-24	-12	8.74	-24
Net Income / (Loss) Continuing Operations	-19	-17	0.91	-20	-24	-12	8.74	-24
Total Pre-Tax Income	-19	-17	0.73	-26	-24	-10	6.09	-25
Total Operating Income	-15	-14	-14	-17	-26	-16	-8.50	-19
Total Gross Profit	54	59	65	70	70	74	80	84
Total Revenue	55	60	65	70	71	75	80	84
Operating Revenue	55	60	65	70	71	75	80	84
Total Cost of Revenue	0.22	0.35	0.28	0.20	0.25	1.71	0.45	0.33
Operating Cost of Revenue	0.22	0.35	0.28	0.20	0.25	1.71	0.45	0.33
Total Operating Expenses	69	73	79	87	97	90	88	103
Selling, General & Admin Expense	33	35	35	41	39	39	36	42
Research & Development Expense	37	38	43	46	57	51	53	61
Total Other Income / (Expense), net	-4.46	-3.07	15	-8.59	2.41	5.89	15	-5.37
Interest Expense	1.25	1.27	1.32	1.31	3.24	4.28	4.29	7.04
Interest & Investment Income	3.13	4.28	5.14	5.44	8.25	6.24	5.96	5.17
Other Income / (Expense), net	-6.34	-6.07	11	-13	-2.60	3.93	13	-3.50
Income Tax Expense	0.29	0.19	-0.18	-5.91	0.36	1.49	-2.64	-1.05
Basic Earnings per Share	($0.40)	($0.35)	$0.02	($0.40)	($0.49)	($0.23)	$0.17	($0.47)
Weighted Average Basic Shares Outstanding	48.18M	48.69M	49.13M	48.89M	49.88M	50.01M	50.02M	49.99M
Diluted Earnings per Share	($0.40)	($0.35)	$0.02	($0.40)	($0.49)	($0.23)	$0.17	($0.47)
Weighted Average Diluted Shares Outstanding	48.18M	48.69M	54.16M	48.89M	49.88M	50.01M	52.81M	49.99M
Weighted Average Basic & Diluted Shares Outstanding	-	-	-	49.82M	50.01M	50.02M	50.03M	50.07M

This table details how cash moves in and out of Immunocore's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	53	-67	-181	144	94	32	15
Net Cash From Operating Activities	-21	-136	-126	-143	-49	2.94	26
Net Cash From Continuing Operating Activities	-14	-172	-126	-143	-49	2.94	26
Net Income / (Loss) Continuing Operations	-91	-138	-101	-180	-53	-55	-51
Consolidated Net Income / (Loss)	-91	-138	-101	-180	-53	-55	-51
Depreciation Expense	8.17	12	12	7.59	5.34	4.09	4.20
Non-Cash Adjustments To Reconcile Net Income	62	-15	-3.91	49	22	48	28
Changes in Operating Assets and Liabilities, net	5.87	-31	-34	-22	-24	5.78	45
Net Cash From Investing Activities	74	-3.46	0.00	-1.28	-2.20	-5.43	-355
Net Cash From Continuing Investing Activities	74	-3.46	0.00	-1.28	-2.20	-5.43	-355
Purchase of Property, Plant & Equipment	-4.44	-5.67	-	-1.39	-2.20	-5.43	-5.17
Purchase of Investments	-0.06	-	-	-	0.00	0.00	-350
Sale of Property, Plant & Equipment	0.00	0.11	-	0.11	0.01	0.00	0.04
Net Cash From Financing Activities	0.13	73	-55	288	145	34	344
Net Cash From Continuing Financing Activities	0.13	73	-55	288	145	34	344
Repayment of Debt	0.00	-5.35	-	0.00	-54	0.00	-65
Other Financing Activities, net	0.13	0.04	-55	288	199	34	409
Cash Interest Received	-	-	-	-	-4.48	5.67	-9.24
Cash Income Taxes Paid	-	-	-	17	0.77	0.98	0.51

This table details how cash moves in and out of Immunocore's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	14	10	20	-12	391	-328	20	-69
Net Cash From Operating Activities	11	0.05	10	-18	-4.59	23	21	-14
Net Cash From Continuing Operating Activities	11	0.05	10	-18	-4.59	23	21	-14
Net Income / (Loss) Continuing Operations	-19	-17	0.91	-20	-24	-12	8.74	-24
Consolidated Net Income / (Loss)	-19	-17	0.91	-20	-24	-12	8.74	-24
Depreciation Expense	0.95	1.03	1.08	1.03	1.01	0.99	1.04	1.17
Non-Cash Adjustments To Reconcile Net Income	16	13	-2.66	22	11	6.87	-6.66	17
Changes in Operating Assets and Liabilities, net	13	2.57	11	-21	8.14	27	18	-8.25
Net Cash From Investing Activities	-3.00	-1.40	-0.21	-0.82	-0.43	-350	-0.83	-3.54
Net Cash From Continuing Investing Activities	-3.00	-1.40	-0.21	-0.82	-0.43	-350	-0.83	-3.54
Purchase of Property, Plant & Equipment	-3.00	-1.40	-0.21	-0.82	-0.43	-0.33	-0.83	-3.58
Net Cash From Financing Activities	6.14	12	10	6.25	396	-0.82	0.20	-52
Net Cash From Continuing Financing Activities	6.14	12	10	6.25	396	-0.82	0.20	-52
Repayment of Debt	0.00	-	-	-	-12	-1.12	-	-52
Other Financing Activities, net	6.14	12	10	6.25	408	0.30	0.20	0.55
Cash Interest Received	1.58	2.87	1.25	-0.03	5.14	6.98	-4.83	-17
Cash Income Taxes Paid	-0.22	0.44	-	0.76	-0.14	0.20	0.29	0.16

This table presents Immunocore's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Total Assets	246	269	407	527	597	1,010
Total Current Assets	165	209	355	474	529	930
Cash & Equivalents	98	177	321	402	443	456
Short-Term Investments	0.35	0.00	-	-	0.00	365
Accounts Receivable	13	14	21	34	52	63
Inventories, net	-	-	0.00	0.69	4.50	5.45
Prepaid Expenses	-	-	-	37	30	41
Plant, Property, & Equipment, net	24	19	12	7.83	9.22	10
Total Noncurrent Assets	57	42	41	45	59	70
Noncurrent Deferred & Refundable Income Taxes	2.00	3.05	3.48	5.12	11	15
Other Noncurrent Operating Assets	55	39	37	40	48	55
Total Liabilities & Shareholders' Equity	246	269	407	527	597	1,010
Total Liabilities	226	194	176	188	228	649
Total Current Liabilities	112	75	83	101	139	212
Accounts Payable	39	35	48	14	18	25
Accrued Expenses	38	-	-	77	120	186
Other Current Liabilities	9.62	40	35	1.88	1.39	1.55
Total Noncurrent Liabilities	114	119	93	87	89	437
Long-Term Debt	0.00	50	50	48	48	391
Noncurrent Deferred Revenue	64	-	-	5.24	5.52	5.43
Other Noncurrent Operating Liabilities	0.14	34	8.73	34	36	40
Commitments & Contingencies	-	-	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	20	76	232	339	369	361
Total Preferred & Common Equity	20	76	232	339	369	361
Total Common Equity	-356	76	-55	339	369	361
Common Stock	0.00	0.09	0.12	1,083	1,150	1,190
Retained Earnings	-370	-478	-650	-689	-745	-796
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-55	-36	-34
Other Equity Adjustments	14	553	595	0.00	0.00	0.00

This table presents Immunocore's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024
Total Assets	994	1,023	1,085
Total Current Assets	926	957	1,006
Cash & Equivalents	833	505	538
Short-Term Investments	-	355	364
Accounts Receivable	58	60	64
Inventories, net	4.17	3.46	4.52
Prepaid Expenses	31	34	36
Plant, Property, & Equipment, net	8.38	7.68	9.16
Total Noncurrent Assets	60	59	70
Noncurrent Deferred & Refundable Income Taxes	11	10	13
Other Noncurrent Operating Assets	49	49	57
Total Liabilities & Shareholders' Equity	994	1,023	1,085
Total Liabilities	634	664	707
Total Current Liabilities	155	185	266
Short-Term Debt	-	-	48
Accounts Payable	16	20	20
Accrued Expenses	139	164	197
Other Current Liabilities	1.24	1.39	1.10
Total Noncurrent Liabilities	479	479	441
Long-Term Debt	438	438	390
Noncurrent Deferred Revenue	5.47	5.48	5.80
Other Noncurrent Operating Liabilities	36	36	44
Total Equity & Noncontrolling Interests	360	359	378
Total Preferred & Common Equity	360	359	378
Total Common Equity	360	359	378
Common Stock	1,164	1,174	1,181
Retained Earnings	-769	-781	-772
Accumulated Other Comprehensive Income / (Loss)	-35	-34	-31
Other Equity Adjustments	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Immunocore's official financial filings.

Metric	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	12.87%	46.81%	-26.94%	377.91%	43.05%	24.37%
EBITDA Growth	0.00%	-30.82%	25.96%	-53.86%	79.42%	-105.43%	20.29%
EBIT Growth	0.00%	-31.68%	23.90%	-46.15%	77.50%	-87.92%	19.01%
NOPAT Growth	0.00%	-31.68%	23.90%	-46.33%	70.38%	-15.36%	-18.13%
Net Income Growth	0.00%	-50.91%	26.52%	-77.91%	70.81%	-5.22%	7.60%
EPS Growth	0.00%	-40.36%	40.13%	-51.97%	72.88%	1.74%	9.73%
Operating Cash Flow Growth	0.00%	-543.74%	7.33%	-13.26%	65.61%	105.97%	786.43%
Free Cash Flow Firm Growth	0.00%	0.00%	35.51%	-94.37%	81.00%	-24.45%	79.69%
Invested Capital Growth	0.00%	0.00%	-543.89%	70.34%	-210.69%	-63.51%	-166.36%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.69%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	11.13%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.24%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.53%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8.59%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-7.37%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.98%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	19.01%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	90.77%	100.00%	99.38%	99.58%	99.12%
EBITDA Margin	-366.74%	-425.05%	-214.37%	-451.44%	-19.44%	-27.92%	-17.89%
Operating Margin	-395.09%	-460.95%	-238.92%	-478.53%	-29.66%	-23.91%	-22.71%
EBIT Margin	-395.09%	-460.95%	-238.92%	-477.94%	-22.50%	-29.56%	-19.25%
Profit (Net Income) Margin	-302.82%	-404.89%	-202.64%	-493.45%	-30.13%	-22.17%	-16.47%
Tax Burden Percent	81.23%	82.36%	84.81%	100.08%	128.52%	90.80%	96.51%
Interest Burden Percent	94.35%	106.65%	100.00%	103.16%	104.21%	82.59%	88.66%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-703.62%	-212.67%	-117.22%	-18.42%	-15.62%	-14.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-63.73%	-46.31%	-51.54%	-8.40%	-13.12%	-7.43%
Return on Assets (ROA)	0.00%	-55.98%	-39.27%	-53.21%	-11.25%	-9.84%	-6.36%
Return on Common Equity (ROCE)	0.00%	12,788.97%	626.16%	-7.88%	-9.17%	-15.62%	-14.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-703.62%	-133.87%	-77.74%	-15.50%	-14.99%	-14.16%
Net Operating Profit after Tax (NOPAT)	-83	-110	-84	-122	-36	-42	-49
NOPAT Margin	-276.56%	-322.66%	-167.25%	-334.97%	-20.76%	-16.74%	-15.90%
Net Nonoperating Expense Percent (NNEP)	0.00%	-251.63%	-30.76%	-35.11%	-5.53%	-3.61%	-0.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-9.36%	-10.02%	-6.56%
Cost of Revenue to Revenue	0.00%	0.00%	9.23%	0.00%	0.62%	0.42%	0.88%
SG&A Expenses to Revenue	144.40%	172.13%	125.10%	303.76%	70.58%	57.93%	50.22%
R&D to Revenue	353.32%	389.54%	204.60%	274.77%	58.45%	65.57%	71.61%
Operating Expenses to Revenue	497.42%	561.67%	329.69%	578.53%	129.03%	123.50%	121.83%
Earnings before Interest and Taxes (EBIT)	-119	-157	-119	-174	-39	-74	-60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-111	-145	-107	-165	-34	-70	-56
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	3.42	0.00	7.39	8.91	4.09
Price to Tangible Book Value (P/TBV)	0.00	0.00	3.42	0.00	7.39	8.91	4.09
Price to Revenue (P/Rev)	8.57	7.60	5.17	29.83	14.36	13.17	4.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	17.98	3.32	31.19	12.32	11.59	3.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	983.26	40.16
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	3.89	1.12	0.36	0.14	0.13	1.08
Long-Term Debt to Equity	0.00	2.59	1.12	0.36	0.14	0.13	1.08
Financial Leverage	0.00	-1.14	-1.21	-1.07	-1.04	-1.06	-1.13
Leverage Ratio	0.00	12.57	5.42	2.20	1.64	1.59	2.20
Compound Leverage Factor	0.00	13.40	5.42	2.27	1.71	1.31	1.95
Debt to Total Capital	0.00%	79.55%	52.77%	26.73%	12.36%	11.52%	52.02%
Short-Term Debt to Total Capital	0.00%	26.52%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	53.03%	52.77%	26.73%	12.36%	11.52%	52.02%
Preferred Equity to Total Capital	0.00%	392.17%	0.00%	90.65%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-371.72%	47.23%	-17.38%	87.64%	88.48%	47.98%
Debt to EBITDA	0.00	-0.53	-0.79	-0.51	-1.41	-0.69	-7.04
Net Debt to EBITDA	0.00	0.15	0.87	1.44	10.46	5.67	7.74
Long-Term Debt to EBITDA	0.00	-0.35	-0.79	-0.51	-1.41	-0.69	-7.04
Debt to NOPAT	0.00	-0.69	-1.01	-0.69	-1.32	-1.15	-7.93
Net Debt to NOPAT	0.00	0.20	1.11	1.94	9.80	9.45	8.71
Long-Term Debt to NOPAT	0.00	-0.46	-1.01	-0.69	-1.32	-1.15	-7.93
Altman Z-Score	0.00	-3.13	-2.36	0.96	7.10	7.69	1.23
Noncontrolling Interest Sharing Ratio	0.00%	1,917.61%	394.42%	93.28%	50.22%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	1.47	2.78	4.29	4.70	3.80	4.38
Quick Ratio	0.00	0.99	2.55	4.14	4.32	3.56	4.16
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-107	-69	-134	-26	-32	-6.45
Operating Cash Flow to CapEx	-476.94%	-2,453.53%	0.00%	-11,180.16%	-2,239.83%	54.19%	508.11%
Free Cash Flow to Firm to Interest Expense	0.00	-8.62	0.00	-24.09	-4.72	-6.16	-0.34
Operating Cash Flow to Interest Expense	0.00	-10.97	0.00	-25.68	-9.10	0.57	1.38
Operating Cash Flow Less CapEx to Interest Expense	0.00	-11.42	0.00	-25.91	-9.50	-0.48	1.11
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.14	0.19	0.11	0.37	0.44	0.39
Accounts Receivable Turnover	0.00	2.66	3.72	2.11	6.44	5.82	5.39
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.40	0.55
Fixed Asset Turnover	0.00	1.40	2.32	2.36	17.52	29.26	32.13
Accounts Payable Turnover	0.00	0.00	0.12	0.00	0.04	0.06	0.13
Days Sales Outstanding (DSO)	0.00	137.06	97.99	172.93	56.64	62.69	67.72
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	913.91	664.71
Days Payable Outstanding (DPO)	0.00	0.00	2,939.00	0.00	10,438.63	5,675.27	2,866.67
Cash Conversion Cycle (CCC)	0.00	137.06	-2,841.01	172.93	-10,381.99	-4,698.68	-2,134.24
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	-2.66	-17	-5.07	-16	-26	-69
Invested Capital Turnover	0.00	-25.61	-5.05	-3.29	-16.74	-12.01	-6.57
Increase / (Decrease) in Invested Capital	0.00	-2.66	-14	12	-11	-10	-43
Enterprise Value (EV)	0.00	611	166	1,138	2,149	2,891	1,047
Market Capitalization	258	258	258	1,088	2,503	3,285	1,476
Book Value per Share	$0.00	($35.81)	$2.38	($1.73)	$7.73	$7.67	$7.21
Tangible Book Value per Share	$0.00	($35.81)	$2.38	($1.73)	$7.73	$7.67	$7.21
Total Capital	0.00	96	160	316	387	417	752
Total Debt	0.00	76	84	84	48	48	391
Total Long-Term Debt	0.00	51	84	84	48	48	391
Net Debt	0.00	-22	-93	-237	-355	-395	-429
Capital Expenditures (CapEx)	4.44	5.56	0.00	1.28	2.20	5.43	5.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-20	-43	-49	-29	-53	-103
Debt-free Net Working Capital (DFNWC)	0.00	78	134	272	373	390	718
Net Working Capital (NWC)	0.00	53	134	272	373	390	718
Net Nonoperating Expense (NNE)	7.91	28	18	58	16	14	1.76
Net Nonoperating Obligations (NNO)	0.00	-22	-93	-237	-355	-395	-429
Total Depreciation and Amortization (D&A)	8.54	12	12	9.67	5.34	4.09	4.20
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-59.63%	-86.92%	-134.47%	-16.82%	-21.18%	-33.11%
Debt-free Net Working Capital to Revenue	0.00%	229.56%	267.84%	745.77%	214.01%	156.28%	231.36%
Net Working Capital to Revenue	0.00%	154.93%	267.84%	745.77%	214.01%	156.28%	231.36%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($3.10)	($0.90)	($1.13)	($1.02)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	31.78M	43.86M	48.09M	48.89M	49.99M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($3.10)	($0.90)	($1.13)	($1.02)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	31.78M	43.86M	48.09M	48.89M	49.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	31.78M	43.86M	48.09M	49.82M	50.07M
Normalized Net Operating Profit after Tax (NOPAT)	-83	-110	-84	-122	-36	-42	-49
Normalized NOPAT Margin	-276.56%	-322.66%	-167.25%	-334.97%	-20.76%	-16.74%	-15.90%
Pre Tax Income Margin	-372.78%	-491.60%	-238.92%	-493.04%	-23.45%	-24.41%	-17.07%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-12.62	0.00	-31.29	-7.25	-14.30	-3.17
NOPAT to Interest Expense	0.00	-8.83	0.00	-21.93	-6.69	-8.10	-2.62
EBIT Less CapEx to Interest Expense	0.00	-13.06	0.00	-31.52	-7.66	-15.36	-3.44
NOPAT Less CapEx to Interest Expense	0.00	-9.28	0.00	-22.16	-7.10	-9.15	-2.89
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.71%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Immunocore's official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	28.99%	26.18%	23.74%	19.80%
EBITDA Growth	0.00%	0.00%	0.00%	0.00%	-39.80%	40.95%	371.14%	24.18%
EBIT Growth	0.00%	0.00%	0.00%	0.00%	-38.28%	39.01%	243.14%	22.89%
NOPAT Growth	0.00%	0.00%	0.00%	0.00%	-80.25%	-16.43%	30.46%	-14.07%
Net Income Growth	0.00%	0.00%	0.00%	0.00%	-25.64%	31.73%	864.24%	-20.48%
EPS Growth	0.00%	0.00%	0.00%	0.00%	-22.50%	34.29%	750.00%	-17.50%
Operating Cash Flow Growth	0.00%	0.00%	0.00%	0.00%	-143.52%	52,060.00%	109.41%	21.33%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-166.36%
Revenue Q/Q Growth	0.00%	9.33%	8.52%	8.19%	0.00%	6.95%	6.43%	4.74%
EBITDA Q/Q Growth	0.00%	6.39%	89.29%	-1,327.67%	0.00%	60.46%	149.17%	-499.23%
EBIT Q/Q Growth	0.00%	5.74%	84.42%	-863.46%	0.00%	58.43%	136.58%	-619.01%
NOPAT Q/Q Growth	0.00%	6.39%	-82.04%	31.91%	0.00%	39.54%	-8.72%	-11.70%
Net Income Q/Q Growth	0.00%	12.52%	105.33%	-2,277.70%	0.00%	52.46%	175.21%	-372.10%
EPS Q/Q Growth	0.00%	12.50%	105.71%	-2,100.00%	0.00%	53.06%	173.91%	-376.47%
Operating Cash Flow Q/Q Growth	0.00%	-99.57%	22,320.00%	-275.77%	0.00%	611.71%	-9.99%	-166.03%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	197.25%	41.94%	-59.68%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-74.41%	-35.97%	19.01%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	99.60%	99.42%	99.57%	99.72%	99.65%	97.74%	99.44%	99.61%
EBITDA Margin	-36.74%	-31.46%	-3.10%	-40.96%	-39.82%	-14.72%	6.80%	-25.92%
Operating Margin	-26.89%	-23.02%	-21.81%	-24.30%	-37.57%	-21.24%	-10.59%	-23.14%
EBIT Margin	-38.48%	-33.18%	-4.76%	-42.43%	-41.26%	-16.04%	5.51%	-27.31%
Profit (Net Income) Margin	-35.58%	-28.47%	1.40%	-28.12%	-34.66%	-15.41%	10.89%	-28.28%
Tax Burden Percent	101.53%	101.14%	123.94%	76.94%	101.48%	114.67%	143.38%	95.77%
Interest Burden Percent	91.07%	84.85%	-23.66%	86.13%	82.79%	83.77%	137.76%	108.12%
Effective Tax Rate	0.00%	0.00%	-23.94%	0.00%	0.00%	0.00%	-43.38%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	0.00%	0.00%	-15.62%	-16.76%	-15.28%	-12.45%	-14.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-18.84%	-11.01%	-4.40%	1.51%	-10.55%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-12.48%	-9.25%	-4.23%	2.97%	-10.92%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	-15.62%	-16.76%	-15.28%	-12.45%	-14.00%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%	-16.76%	-15.28%	-12.45%	0.00%
Net Operating Profit after Tax (NOPAT)	-10	-9.63	-18	-12	-19	-11	-12	-14
NOPAT Margin	-18.82%	-16.12%	-27.03%	-17.01%	-26.30%	-14.87%	-15.19%	-16.20%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.00%	0.00%	-1.98%	-2.98%	-0.19%	9.05%	-2.46%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-2.86%	-	-	-	-1.81%
Cost of Revenue to Revenue	0.40%	0.58%	0.43%	0.28%	0.35%	2.26%	0.56%	0.39%
SG&A Expenses to Revenue	59.58%	58.59%	54.69%	59.08%	55.72%	51.24%	44.28%	50.35%
R&D to Revenue	66.91%	63.86%	66.69%	64.94%	81.50%	67.73%	65.76%	72.40%
Operating Expenses to Revenue	126.49%	122.44%	121.38%	124.02%	137.22%	118.98%	110.04%	122.75%
Earnings before Interest and Taxes (EBIT)	-21	-20	-3.09	-30	-29	-12	4.42	-23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-19	-2.01	-29	-28	-11	5.46	-22
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	8.91	8.69	4.72	4.12	4.09
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	8.91	8.69	4.72	4.12	4.09
Price to Revenue (P/Rev)	0.00	0.00	0.00	13.17	11.78	6.03	5.25	4.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	11.59	10.29	4.53	3.69	3.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	983.26	0.00	113.28	49.13	40.16
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.13	1.22	1.22	1.16	1.08
Long-Term Debt to Equity	0.00	0.00	0.00	0.13	1.22	1.22	1.03	1.08
Financial Leverage	0.00	0.00	0.00	-1.07	-1.10	-1.17	-1.22	-1.13
Leverage Ratio	0.00	0.00	0.00	1.59	2.76	2.85	2.87	2.20
Compound Leverage Factor	0.00	0.00	0.00	1.37	2.29	2.39	3.95	2.38
Debt to Total Capital	0.00%	0.00%	0.00%	11.52%	54.89%	54.95%	53.73%	52.02%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.90%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	11.52%	54.89%	54.95%	47.82%	52.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	0.00%	0.00%	88.48%	45.11%	45.05%	46.27%	47.98%
Debt to EBITDA	0.00	0.00	0.00	-0.69	-5.64	-6.27	-7.02	-7.04
Net Debt to EBITDA	0.00	0.00	0.00	5.67	5.09	6.03	7.41	7.74
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.69	-5.64	-6.27	-6.25	-7.04
Debt to NOPAT	0.00	0.00	0.00	-1.15	-8.75	-8.49	-9.21	-7.93
Net Debt to NOPAT	0.00	0.00	0.00	9.45	7.90	8.17	9.71	8.71
Long-Term Debt to NOPAT	0.00	0.00	0.00	-1.15	-8.75	-8.49	-8.20	-7.93
Altman Z-Score	0.00	0.00	0.00	7.93	2.97	1.60	1.43	1.35
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	0.00	0.00	3.80	5.96	5.17	3.78	4.38
Quick Ratio	0.00	0.00	0.00	3.56	5.73	4.97	3.62	4.16
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	0.00	0.00	17	51	73	29
Operating Cash Flow to CapEx	351.18%	3.23%	4,758.96%	-2,170.50%	-1,066.74%	7,091.24%	2,551.57%	-389.26%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	5.31	11.95	16.92	4.16
Operating Cash Flow to Interest Expense	8.43	0.04	7.64	-13.55	-1.42	5.49	4.92	-1.98
Operating Cash Flow Less CapEx to Interest Expense	6.03	-1.06	7.48	-14.17	-1.55	5.41	4.73	-2.49
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.44	0.27	0.27	0.27	0.39
Accounts Receivable Turnover	0.00	0.00	0.00	5.82	4.59	4.66	4.65	5.39
Inventory Turnover	0.00	0.00	0.00	0.40	0.26	0.70	0.58	0.55
Fixed Asset Turnover	0.00	0.00	0.00	29.26	31.66	36.56	32.35	32.13
Accounts Payable Turnover	0.00	0.00	0.00	0.06	0.07	0.12	0.13	0.13
Days Sales Outstanding (DSO)	0.00	0.00	0.00	62.69	79.47	78.28	78.42	67.72
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	913.91	1,425.45	520.44	634.26	664.71
Days Payable Outstanding (DPO)	0.00	0.00	0.00	5,675.27	5,302.59	2,998.62	2,768.53	2,866.67
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	-4,698.68	-3,797.67	-2,399.90	-2,055.85	-2,134.24
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	0.00	0.00	-26	-36	-62	-85	-69
Invested Capital Turnover	0.00	0.00	0.00	-9.68	-14.84	-9.01	-6.99	-6.57
Increase / (Decrease) in Invested Capital	0.00	0.00	0.00	0.00	-36	-62	-85	-43
Enterprise Value (EV)	0.00	0.00	0.00	2,891	2,730	1,273	1,094	1,047
Market Capitalization	2,377	2,883	2,496	3,285	3,126	1,695	1,557	1,476
Book Value per Share	$0.00	$0.00	$0.00	$7.67	$7.21	$7.18	$7.55	$7.21
Tangible Book Value per Share	$0.00	$0.00	$0.00	$7.67	$7.21	$7.18	$7.55	$7.21
Total Capital	0.00	0.00	0.00	417	797	797	817	752
Total Debt	0.00	0.00	0.00	48	438	438	439	391
Total Long-Term Debt	0.00	0.00	0.00	48	438	438	390	391
Net Debt	0.00	0.00	0.00	-395	-395	-421	-463	-429
Capital Expenditures (CapEx)	3.00	1.40	0.21	0.82	0.43	0.33	0.83	3.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.00	0.00	-53	-62	-88	-113	-103
Debt-free Net Working Capital (DFNWC)	0.00	0.00	0.00	390	771	772	788	718
Net Working Capital (NWC)	0.00	0.00	0.00	390	771	772	740	718
Net Nonoperating Expense (NNE)	9.16	7.38	-18	7.79	5.89	0.40	-21	10
Net Nonoperating Obligations (NNO)	0.00	0.00	0.00	-395	-395	-421	-463	-429
Total Depreciation and Amortization (D&A)	0.95	1.03	1.08	1.03	1.01	0.99	1.04	1.17
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-21.18%	-23.40%	-31.27%	-38.28%	-33.11%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	156.28%	290.55%	274.73%	265.89%	231.36%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	156.28%	290.55%	274.73%	249.62%	231.36%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($0.40)	($0.49)	($0.23)	$0.17	($0.47)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	48.89M	49.88M	50.01M	50.02M	49.99M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.40)	($0.49)	($0.23)	$0.17	($0.47)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	48.89M	49.88M	50.01M	52.81M	49.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	49.82M	50.01M	50.02M	50.03M	50.07M
Normalized Net Operating Profit after Tax (NOPAT)	-10	-9.63	-9.90	-12	-19	-11	-5.95	-14
Normalized NOPAT Margin	-18.82%	-16.12%	-15.27%	-17.01%	-26.30%	-14.87%	-7.42%	-16.20%
Pre Tax Income Margin	-35.05%	-28.15%	1.13%	-36.55%	-34.15%	-13.44%	7.59%	-29.53%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-16.83	-15.56	-2.34	-22.74	-8.98	-2.83	1.03	-3.26
NOPAT to Interest Expense	-8.23	-7.56	-13.27	-9.12	-5.72	-2.62	-2.84	-1.93
EBIT Less CapEx to Interest Expense	-19.23	-16.66	-2.50	-23.37	-9.11	-2.90	0.84	-3.77
NOPAT Less CapEx to Interest Expense	-10.63	-8.65	-13.43	-9.74	-5.86	-2.70	-3.03	-2.44
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Immunocore's Financials

When does Immunocore's financial year end?

According to the most recent income statement we have on file, Immunocore's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Immunocore's net income changed over the last 6 years?

Immunocore's net income appears to be on a downward trend, with a most recent value of -$51.09 million in 2024, falling from -$91.26 million in 2018. The previous period was -$55.29 million in 2023.

What is Immunocore's operating income?

Immunocore's total operating income in 2024 was -$70.46 million, based on the following breakdown:

Total Gross Profit: $307.47 million
Total Operating Expenses: $377.93 million

How has Immunocore revenue changed over the last 6 years?

Over the last 6 years, Immunocore's total revenue changed from $30.13 million in 2018 to $310.20 million in 2024, a change of 929.4%.

How much debt does Immunocore have?

Immunocore's total liabilities were at $648.79 million at the end of 2024, a 184.4% increase from 2023, and a 186.5% increase since 2019.

How much cash does Immunocore have?

In the past 5 years, Immunocore's cash and equivalents has ranged from $98.01 million in 2019 to $455.73 million in 2024, and is currently $455.73 million as of their latest financial filing in 2024.

How has Immunocore's book value per share changed over the last 6 years?

Over the last 6 years, Immunocore's book value per share changed from 0.00 in 2018 to 7.21 in 2024, a change of 721.0%.

Remove Ads

Related Companies

This page (NASDAQ:IMCR) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Financials

Frequently Asked Questions About Immunocore's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Financials

Annual Income Statements for Immunocore

Quarterly Income Statements for Immunocore

Annual Cash Flow Statements for Immunocore

Quarterly Cash Flow Statements for Immunocore

Annual Balance Sheets for Immunocore

Quarterly Balance Sheets for Immunocore

Annual Metrics and Ratios for Immunocore

Quarterly Metrics and Ratios for Immunocore

Frequently Asked Questions About Immunocore's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools